CAVA vs REGN · P/E 77, rev $963.7M vs P/E 14, rev $14.34B
CAVA Group, Inc. (CAVA) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
CAVA Group, Inc. (CAVA) is a restaurants company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported CAVA revenue for 2024-12-29 was $963.7M. Net income was $130.3M. Revenue was up 32.3% from 2023-12-31 to 2024-12-29. CAVA currently screens at market cap $10.65B and trailing P/E 76.7.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
CAVA currently screens at market cap $10.65B and trailing P/E 76.7. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the CAVA and REGN stock pages for the full models.
Not investment advice.